PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Prediction of Anthracycline Benefit in Hormone Receptor– Positive, Human Epidermal Growth Factor Receptor 2– Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study

Publication: JCO Precis Oncol, June 2026 DOI https://doi.org/10.1200/PO-25-01285 Authors: Joyce O'Shaughnessy et al. Title: Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer Abstract Purpose: Randomized trials have not demonstrated clear benefit from anthracyclines for patients with hormone receptor–positive, human epidermal growth Read More

Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy

Publication: ASCO 2026, Abstract #621 Authors: David Page Title: Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer Abstract Background: Neoadjuvant outcomes are variable in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), highlighting the unmet need for predictive biomarkers. Read More

Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers

Publication: ASCO 2026, Abstract #561 Authors: Steve Isakoff Title: Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers Abstract Background: Homologous recombination deficiency (HRD) is a biomarker for impaired DNA repair proficiency and genomic instability, associated with sensitivity to DNA-damaging agents. Read More

Genomically Basal-Type tumors demonstrate distinct immune profiles and chemosensitivity across self-reported race among patients enrolled in FLEX receiving neoadjuvant chemotherapy

Publication: ASBrS 2026, Abstract Number: 1062 Authors:Nathalie Johnson, Mehran Habibi, Marcela Mazo, Ahmed Elkhanany, Fengting Yan, Nicole Sookhan, J. Jaime Alberty-Oller, Laila Samiian, Eric Brown, Linsey Gold, Alfredo Santillan, Eduardo Dias, Sasha Davis, Laura Lee, Constantine Godellas, Abigail Beard, Gordan Srkalovic, Beth-Ann Lesnikoski, Sahra Uygun, Christina Page, Nicole Stivers, Read More

Prognostic Value of MammaPrint in Diverse Populations: Evaluating Racial Disparities in Breast Cancer Outcomes

Publication: JCO Precis Oncol. 2026 Apr;10(4):e2500926. doi: 10.1200/PO-25-00926. Epub 2026 Apr 9. Authors: Reine Abou Zeidane, Samuel Lichtman-Mikol, Courtney Pisano, Benjamin Hauk, Yilun Sun, Priyanka S Rana, Citlally Lopez-Flores, Breanna N McBean, Kassidy M Jungles, Trisha Lal, Nihit Mehta, Philip Bomeisl, Amanda L Amin, Alberto J Montero, Siran Koroukian, Read More

Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2- breast cancer

Publication: npj Breast Cancer 12, 68 (2026). https://doi.org/10.1038/s41523-026-00932-1Authors: Sonya Reid; Lindsay Venton; Jennifer G. Whisenant; Anne E. Weidner; Jennifer Wei; Harshini Ramaswamy; Christa Dreezen; Nicole Chmielewski-Stivers;Andrea R. Menicucci; William Audeh; Tuya PalTitle: Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2– breast cancerAbstract:We compared clinicopathologic features, MammaPrint and Read More